Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.
about
Hepatitis B virus molecular biology and pathogenesisClonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection.Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.AASLD guidelines for treatment of chronic hepatitis B.A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B.Emerging drugs for hepatitis B.Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy.Entecavir for the treatment of chronic hepatitis B.Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?Hepatitis B virus-cell interactions and pathogenesis.The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir.Genomic DNA double-strand breaks are targets for hepadnaviral DNA integrationPathobiology of HBV mutants and clinical impact for treatment monitoring.Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop.Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application.Experimental models and therapeutic approaches for HBV.Therapeutic strategies for a functional cure of chronic hepatitis B virus infection.HBV DNA Integration: Molecular Mechanisms and Clinical ImplicationsAnti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.A comparison of clevudine and entecavir for treatment-naïve patients with chronic hepatitis B: results after 2 years of treatment.Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy.Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy.Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via NTCP-dependent uptake of enveloped virus particles.Anti-DNA Virus AgentsClevudine: a promising therapy for the treatment of chronic hepatitis BTreatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study
P2860
Q28818406-0C62AA5E-9E99-4F64-8986-6FBD26214156Q33732314-DE9B1C4E-FB39-46D5-A434-6FB96DD307F1Q34289969-35FBFEF3-CFDF-46EE-9544-C4B24E31F9E4Q34501660-3B824803-C43F-41A3-8793-453F94B13664Q34959568-D4156029-E333-42BD-8780-5231C93511B6Q35359369-DF350A4D-41CD-4A1A-B1BD-42D94D943847Q35846564-35764119-2263-4520-9B48-C608E6EB0AE1Q35964745-A3951948-A877-458D-BC70-D93068E0B8D1Q36007344-809061CA-EC96-48E8-9C8D-163128EFDB84Q37095435-D90F249E-42BB-490C-A41D-8627D91775C4Q37099820-8F63CA61-55D1-4334-93CA-4A36994D7FAEQ37285762-B9AC5CE3-1801-450B-8289-9B8877BF1A6AQ37432098-63A29F72-B826-4044-BDC8-EEFD2DBAC7D7Q37678183-57DE5C6B-1F0B-41BB-9215-895AF7040DEDQ37727852-8E102601-FE0D-4B42-A663-719A2821224BQ38035173-8F5B7F99-79AD-4A9B-8F12-D1B55EDBA16FQ38636988-365662F9-28B4-424F-8784-99A81243E156Q38732528-AA149A6C-06CF-4D5B-B171-A65AC8EC56F6Q39859839-7CD63DB6-AB84-4AED-94DB-7618F375471FQ40707675-9FA81479-FE93-4AEC-8B07-229AC5C7CB97Q43702187-1E0A3C24-D318-49AD-B7D3-2049AEFA5E8AQ45257660-26987F69-616E-40A5-BBBA-E4465D8D0029Q50043349-7F6C7E18-D274-4370-89F7-26D8FBD3E1BEQ56786267-A38C6735-FDD0-4011-BCEB-B394D8954EAFQ57211211-5AA8EB3F-E18C-46BB-A91C-94E81CC39EC7Q58235659-5CB1EFBE-0A16-4CF4-9FEC-68C4308BB524
P2860
Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.
@ast
Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.
@en
type
label
Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.
@ast
Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.
@en
prefLabel
Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.
@ast
Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.
@en
P2860
P356
P1476
Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.
@en
P2093
Jesse Summers
William S Mason
P2860
P304
P356
10.1073/PNAS.0307422100
P407
P577
2003-12-29T00:00:00Z